E.g., 05/24/2020
E.g., 05/24/2020

bioMérieux receives FDA clearance to extend platelet shelf life to 7 days with Large Volume Delayed Sampling strategy using BACT/ALERT® 3D and BACT/ALERT® VIRTUO® culture systems.

22 May, 2020

bioMérieux announces that its BACT/ALERT® BPA and BPN culture bottles have received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Large Volume Delayed Sampling (LVDS) of leukocyte-reduced apheresis platelets (LRAP) and leukocyte-reduced whole blood platelet concentrates (LRWBPC) with BACT/ALERT®3D and BACT/ALERT® VIRTUO® systems.

CE marking of bioMérieux serology tests for SARS-CoV-2 on VIDAS®

21 May, 2020

bioMérieux announced the CE marking of VIDAS anti-SARS-CoV-2 serology tests to detect antibodies in people who have been exposed to SARS-CoV-2 which causes the COVID-19 disease.

Memorial Day Shipping Schedule

12 May, 2020

Please be advised that major delivery services in the U.S. will be closed on Monday, May 25, 2020 in observance of the Memorial Day holiday. We encourage you to place orders with the following dates in mind.

bioMérieux serology tests for SARS-CoV-2 on VIDAS® undergo validation preceding imminent launch

06 May, 2020

bioMérieux announces the upcoming launch of VIDAS® anti-SARS-CoV-2 serology tests to detect antibodies in people who have been exposed to the SARS-CoV-2, complementing its existing COVID-19 solutions.

BIOFIRE® Respiratory Panel 2.1 (RP2.1) with SARS-CoV-2 obtains FDA Emergency Use Authorization

04 May, 2020

BioFire Diagnostics, a bioMérieux subsidiary, has received Emergency Use Authorization by the U.S. Food and Drug Administration of its BIOFIRE® RP2.1 panel, which includes 22 pathogens that cause respiratory infections, including SARS-CoV-2 (the cause of COVID-19 disease).

bioMérieux – First-Quarter 2020 Business Review

16 April, 2020

Marcy l'Étoile (France), April 16, 2020 – bioMérieux, a world leader in the field of in vitro diagnostics, released its business review for the three months ended March 31, 2020.

bioMérieux receives Emergency Use Authorization for BIOFIRE® COVID-19 test

24 March, 2020

BioFire Defense, a bioMérieux subsidiary, has received Emergency Use Authorization by the U.S. Food and Drug Administration of its BIOFIRE® COVID-19 test for use in CLIA moderate and high complexity clinical laboratories to detect SARS-CoV-2.

First of 3 diagnostic tests for SARS-CoV-2 coronavirus available from bioMérieux

11 March, 2020

bioMérieux has finalized the development of the SARS-COV-2 R-GENE® test. This realtime PCR test is clinically validated on one type of respiratory specimen and will be available at the end of March.

Holiday Shipping Schedule

09 January, 2020

Please be advised that bioMérieux Inc. sites in Durham, NC, St. Louis, MO, Louisville, KY, and Lombard, IL will be closed on Monday, January 20, 2020 in observance of Martin Luther King Jr. Day. 

bioMérieux and The Fleming Fund: Working Together to Tackle Antimicrobial Resistance

18 December, 2019

Our partnership with the Fleming Fund will seek to strengthen antimicrobial resistance survillance systems and improve public awareness of AMR in -low and -middle-income countries.